Inhibition of Glypican-3 Cleavage Results in Reduced Cell Proliferation in a Liver Cancer Cell Line
pubmed.ncbi.nlm.nih.gov shows its articles on its own site.
Read the article on pubmed.ncbi.nlm.nih.gov ↗Article · Oct 2022 · 1 min read
In brief
In brief
This study investigates furin-mediated cleavage of glypican-3 (GPC3) in pediatric liver cancer cells, finding that furin inhibition reduces proliferation but paradoxically increases migration in GPC3-positive hepatoblastoma cells. The findings suggest furin is not a viable therapeutic target due to potential enhancement of metastatic behavior.
Written by the GCMD Library team from the article.
Statements in this article
Glypican-3 (GPC3) is a surface-bound proteoglycan overexpressed in pediatric liver cancer and utilized clinically as an immunohistochemical tumor marker.
Furin is a proprotein convertase that is ubiquitously expressed and shown to modify GPC3 post-translationally.
In experimental models of epithelial-based cancers, furin inhibition decreased tumor cell migration and proliferation.
There was a reduction in HepG2 proliferation with addition of furin inhibitor at the 48-h timepoint.
There was an increase in HepG2 migration with furin inhibitor treatment.
Furin inhibition is not an appropriate target for GPC3-expressing hepatoblastoma due to increased migration which may enhance metastatic potential.